Heart failure following oncological treatment

James Marangou, Andrew Redfern, Tony Haddad, James M. Rankin, Girish Dwivedi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review The aim of this review is to give the reader an up-to-date overview of the progress made in the burgeoning field of cardio-oncology, encompassing oncological treatments conferring risk, prediction strategies to identify patients at risk, imaging and biomarker monitoring for emergent or subclinical toxicity and prevention in primary and secondary settings with a focus on heart failure. Recent findings The rapid recent advances in cancer management, particularly with the expansion of targeted and immunotherapies, have led to substantial improvements in outcome, but have also added to the potential causes of cardiac toxicity, which can lead to heart failure. Against this, there has been progression in the field of imaging for cardiac toxicity, identification of at-risk individuals and the clarification of the role of therapy for prevention and treatment of cardiac toxicity. Summary The findings described in this review provide guidance to clinicians in order to direct monitoring strategy and therapy choice, both in the individual with preexisting cardiac comorbidities and in those predicted to be at the highest risk of cardiac toxicity wherever therapy elements carrying cardiac risk are considered oncologically appropriate.

Original languageEnglish
Pages (from-to)237-244
Number of pages8
JournalCurrent Opinion in Cardiology
Volume33
Issue number2
DOIs
Publication statusPublished - 1 Mar 2018

Fingerprint

Heart Failure
Therapeutics
Primary Prevention
Secondary Prevention
Immunotherapy
Comorbidity
Biomarkers
Cardiotoxicity
Neoplasms

Cite this

Marangou, James ; Redfern, Andrew ; Haddad, Tony ; Rankin, James M. ; Dwivedi, Girish. / Heart failure following oncological treatment. In: Current Opinion in Cardiology. 2018 ; Vol. 33, No. 2. pp. 237-244.
@article{4083737eacda4bc2890e7170b38755df,
title = "Heart failure following oncological treatment",
abstract = "Purpose of review The aim of this review is to give the reader an up-to-date overview of the progress made in the burgeoning field of cardio-oncology, encompassing oncological treatments conferring risk, prediction strategies to identify patients at risk, imaging and biomarker monitoring for emergent or subclinical toxicity and prevention in primary and secondary settings with a focus on heart failure. Recent findings The rapid recent advances in cancer management, particularly with the expansion of targeted and immunotherapies, have led to substantial improvements in outcome, but have also added to the potential causes of cardiac toxicity, which can lead to heart failure. Against this, there has been progression in the field of imaging for cardiac toxicity, identification of at-risk individuals and the clarification of the role of therapy for prevention and treatment of cardiac toxicity. Summary The findings described in this review provide guidance to clinicians in order to direct monitoring strategy and therapy choice, both in the individual with preexisting cardiac comorbidities and in those predicted to be at the highest risk of cardiac toxicity wherever therapy elements carrying cardiac risk are considered oncologically appropriate.",
keywords = "cardiac imaging, cardio-toxicity, cardiomyopathy, chemotherapy, radiotherapy, targeted-therapy",
author = "James Marangou and Andrew Redfern and Tony Haddad and Rankin, {James M.} and Girish Dwivedi",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/HCO.0000000000000488",
language = "English",
volume = "33",
pages = "237--244",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

Heart failure following oncological treatment. / Marangou, James; Redfern, Andrew; Haddad, Tony; Rankin, James M.; Dwivedi, Girish.

In: Current Opinion in Cardiology, Vol. 33, No. 2, 01.03.2018, p. 237-244.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Heart failure following oncological treatment

AU - Marangou, James

AU - Redfern, Andrew

AU - Haddad, Tony

AU - Rankin, James M.

AU - Dwivedi, Girish

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose of review The aim of this review is to give the reader an up-to-date overview of the progress made in the burgeoning field of cardio-oncology, encompassing oncological treatments conferring risk, prediction strategies to identify patients at risk, imaging and biomarker monitoring for emergent or subclinical toxicity and prevention in primary and secondary settings with a focus on heart failure. Recent findings The rapid recent advances in cancer management, particularly with the expansion of targeted and immunotherapies, have led to substantial improvements in outcome, but have also added to the potential causes of cardiac toxicity, which can lead to heart failure. Against this, there has been progression in the field of imaging for cardiac toxicity, identification of at-risk individuals and the clarification of the role of therapy for prevention and treatment of cardiac toxicity. Summary The findings described in this review provide guidance to clinicians in order to direct monitoring strategy and therapy choice, both in the individual with preexisting cardiac comorbidities and in those predicted to be at the highest risk of cardiac toxicity wherever therapy elements carrying cardiac risk are considered oncologically appropriate.

AB - Purpose of review The aim of this review is to give the reader an up-to-date overview of the progress made in the burgeoning field of cardio-oncology, encompassing oncological treatments conferring risk, prediction strategies to identify patients at risk, imaging and biomarker monitoring for emergent or subclinical toxicity and prevention in primary and secondary settings with a focus on heart failure. Recent findings The rapid recent advances in cancer management, particularly with the expansion of targeted and immunotherapies, have led to substantial improvements in outcome, but have also added to the potential causes of cardiac toxicity, which can lead to heart failure. Against this, there has been progression in the field of imaging for cardiac toxicity, identification of at-risk individuals and the clarification of the role of therapy for prevention and treatment of cardiac toxicity. Summary The findings described in this review provide guidance to clinicians in order to direct monitoring strategy and therapy choice, both in the individual with preexisting cardiac comorbidities and in those predicted to be at the highest risk of cardiac toxicity wherever therapy elements carrying cardiac risk are considered oncologically appropriate.

KW - cardiac imaging

KW - cardio-toxicity

KW - cardiomyopathy

KW - chemotherapy

KW - radiotherapy

KW - targeted-therapy

UR - http://www.scopus.com/inward/record.url?scp=85042543920&partnerID=8YFLogxK

U2 - 10.1097/HCO.0000000000000488

DO - 10.1097/HCO.0000000000000488

M3 - Review article

VL - 33

SP - 237

EP - 244

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 2

ER -